CHMP says yes to developing world vaccine, Novartis' Seebri Breezhaler, Takeda's Revestive
This article was originally published in Scrip
Executive Summary
The European Medicines Agency's scientific committee, the CHMP, has given the green light for the European Commission to OK a number of new medicines, including Takeda's orphan drug Revestive (teduglutide) for patients with short bowel syndrome. And, for the first time ever, it recommended a vaccine – Sanofi Pasteur's Hexaxim – for use in markets outside the EU.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.